Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)

SHA:600521 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	8,656	9,495	8,249	8,183	6,603	6,456
Other Revenue	52.87	52.87	59.54	82.56	40.95	29.5
Revenue	8,709	9,547	8,309	8,266	6,644	6,485
Revenue Growth (YoY)	-6.85%	14.91%	0.52%	24.42%	2.44%	20.36%
Cost of Revenue	3,486	3,738	3,376	3,180	2,671	2,385
Gross Profit	5,222	5,809	4,933	5,086	3,973	4,100
Selling, General & Admin	3,235	3,143	2,592	2,534	2,448	2,080
Research & Development	1,129	986.69	982.99	925.53	942.26	565.7
Other Operating Expenses	39.88	18.41	5.69	3.63	65.21	50.13
Operating Expenses	4,426	4,185	3,572	3,508	3,470	2,725
Operating Income	796.76	1,625	1,360	1,578	502.48	1,375
Interest Expense	-226.73	-219.8	-231.69	-220.02	-166.34	-135.33
Interest & Investment Income	44.46	53.22	39.48	25.83	180.61	19.57
Currency Exchange Gain (Loss)	76.9	76.9	60.1	208.94	-50.99	-145.37
Other Non Operating Income (Expenses)	-19.35	-5.8	-5.14	-3.91	-4.32	-3.86
EBT Excluding Unusual Items	672.04	1,529	1,223	1,589	461.44	1,110
Impairment of Goodwill	-	-	-6.46	-	-	-
Gain (Loss) on Sale of Investments	35.15	-98.21	-162.9	-70	299.81	26.09
Gain (Loss) on Sale of Assets	-0.39	2.33	-0.29	-16.1	-9.59	19.15
Asset Writedown	-65.85	-30.13	-32.95	-2	-0.16	-13.58
Other Unusual Items	60.55	60.55	79.92	8.23	35.42	73.68
Pretax Income	701.5	1,464	1,100	1,509	786.93	1,215
Income Tax Expense	257.36	356.15	283.07	332.89	306.28	220.76
Earnings From Continuing Operations	444.15	1,107	817.25	1,176	480.64	994.6
Minority Interest in Earnings	23.92	11.52	13.22	-8.25	6.89	-64.78
Net Income	468.07	1,119	830.47	1,168	487.54	929.82
Net Income to Common	468.07	1,119	830.47	1,168	487.54	929.82
Net Income Growth	-58.95%	34.74%	-28.88%	139.52%	-47.57%	63.24%
Shares Outstanding (Basic)	1,457	1,449	1,457	1,442	1,434	1,453
Shares Outstanding (Diluted)	1,457	1,449	1,457	1,460	1,434	1,453
Shares Change (YoY)	-0.47%	-0.52%	-0.19%	1.80%	-1.30%	4.58%
EPS (Basic)	0.32	0.77	0.57	0.81	0.34	0.64
EPS (Diluted)	0.32	0.77	0.57	0.80	0.34	0.64
EPS Growth	-59.02%	35.09%	-28.75%	135.29%	-46.88%	56.10%
Free Cash Flow	-956.22	319.33	624.63	-1,074	-1,496	278.97
Free Cash Flow Per Share	-0.66	0.22	0.43	-0.73	-1.04	0.19
Dividend Per Share	0.250	0.250	0.200	0.240	0.100	0.200
Dividend Growth	25.00%	25.00%	-16.67%	140.00%	-50.00%	10.01%
Gross Margin	59.97%	60.85%	59.37%	61.53%	59.80%	63.23%
Operating Margin	9.15%	17.02%	16.37%	19.09%	7.56%	21.20%
Profit Margin	5.38%	11.72%	9.99%	14.13%	7.34%	14.34%
Free Cash Flow Margin	-10.98%	3.35%	7.52%	-12.99%	-22.52%	4.30%
EBITDA	1,761	2,510	2,141	2,230	1,050	1,846
EBITDA Margin	20.23%	26.29%	25.76%	26.98%	15.81%	28.46%
D&A For EBITDA	964.71	885.71	780.37	652.55	547.8	470.83
EBIT	796.76	1,625	1,360	1,578	502.48	1,375
EBIT Margin	9.15%	17.02%	16.37%	19.09%	7.56%	21.20%
Effective Tax Rate	36.69%	24.33%	25.73%	22.06%	38.92%	18.16%
Revenue as Reported	8,709	9,547	8,309	8,266	6,644	6,485
Advertising Expenses	-	1,417	1,036	1,034	999.39	783.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.